Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...